Stock Analysis Report

Executive Summary

Sanofi provides therapeutic solutions worldwide.



Established dividend payer with mediocre balance sheet.

Similar Companies

Share Price & News

How has Sanofi's share price performed over time and what events caused price changes?

Latest Share Price and Events

Market Performance

7 Day Return




CH Pharmaceuticals


CH Market

1 Year Return




CH Pharmaceuticals


CH Market

Shareholder returns

7 Day0%0.5%0.6%
30 Day0%1.8%-0.02%
90 Day0%1.2%1.1%
1 Year6.2%1.8%20.6%10.4%15.6%9.7%
3 Year27.4%12.7%39.8%19.8%33.9%16.5%
5 Yearn/a27.8%3.0%38.0%16.3%

Price Volatility Vs. Market

How volatile is Sanofi's share price compared to the market and industry in the last 5 years?

Simply Wall St News

No news available


Is Sanofi undervalued compared to its fair value and its price relative to the market?


Undervalued compared to fair value

Share Price vs. Fair Value

Undervalued: SAN (CHF86.4) is trading below our estimate of fair value (CHF122.51)

Significantly Undervalued: SAN is trading below fair value, but not by a significant amount.

Price To Earnings Ratio

PE vs Industry: SAN is poor value based on its PE Ratio (27.5x) compared to the Pharmaceuticals industry average (23.9x).

PE vs Market: SAN is poor value based on its PE Ratio (27.5x) compared to the Swiss market (18.5x).

Price to Earnings Growth Ratio

Low PEG Ratio: SAN is poor value based on its PEG Ratio (1.8x)

Price to Book Ratio

PB vs Industry: SAN is good value based on its PB Ratio (1.8x) compared to the CH Pharmaceuticals industry average (3.6x).

Next Steps

Future Growth

How is Sanofi forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SAN's forecast earnings growth (15.3% per year) is above the savings rate (3.3%).

Earnings vs Market: SAN's earnings (15.3% per year) are forecast to grow faster than the Swiss market (10.3% per year).

High Growth Earnings: SAN's earnings are forecast to grow, but not significantly.

Revenue vs Market: SAN's revenue (3% per year) is forecast to grow slower than the Swiss market (3.5% per year).

High Growth Revenue: SAN's revenue (3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Information is not available.

Next Steps

Past Performance

How has Sanofi performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Past Earnings Growth Analysis

Earnings Trend: SAN's earnings have declined by -2.6% per year over the past 5 years.

Accelerating Growth: SAN's earnings growth over the past year (10.7%) exceeds its 5-year average (-2.6% per year).

Earnings vs Industry: SAN earnings growth over the past year (10.7%) underperformed the Pharmaceuticals industry 5.4%.

Return on Equity

High ROE: SAN's Return on Equity (6.5%) is considered low.

Return on Assets

ROA vs Industry: SAN's Return on Assets is below or equal to the Pharmaceuticals industry average last year.

Return on Capital Employed

ROCE Improving: SAN's Return on Capital Employed has declined over the past 3 years.

Next Steps

Financial Health

How is Sanofi's financial position?

Financial Position Analysis

Short Term Liabilities: SAN's short term assets (€25.4B) exceeds its short term liabilities (€19.2B)

Long Term Liabilities: SAN's short term assets (25.4B) do not cover its long term liabilities (34.8B)

Debt to Equity History and Analysis

Debt Level: SAN's debt to equity ratio (45.1%) is considered high

Reducing Debt: SAN's debt to equity ratio has increased from 28.5% to 45.1% over the past 5 years.

Debt Coverage: SAN's debt is well covered by operating cash flow (27.3%).

Interest Coverage: SAN's interest payments on its debt are well covered by EBIT (14.7x coverage).

Balance Sheet

Information is not available.

Information is not available.

Next Steps


What is Sanofi's current dividend yield, its reliability and sustainability?


Current Dividend Yield

Dividend Yield vs Market


Current dividend yield vs market & industry

Stability and Growth of Payments

Notable Dividend: SAN's dividend (3.88%) is higher than the bottom 25% of dividend payers in the Swiss market (1.91%).

High Dividend: SAN's dividend (3.88%) is in the top 25% of dividend payers in the Swiss market (3.7%)

Stable Dividend: SAN's dividends per share have been stable in the past 10 years.

Growing Dividend: SAN's dividend payments have increased over the past 10 years.

Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (106.6%), SAN's dividend payments are not well covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: SAN's dividends in 3 years are forecast to be well covered by earnings (49.7% payout ratio).

Next Steps


What is the CEO of Sanofi's salary, the management and board of directors tenure and is there insider trading?


Average management tenure


Paul Hudson (52yo)




Mr. Paul Hudson serves as Chief Executive Officer of Sanofi since September 1, 2019. Mr. Hudson was Chief Executive Officer of Novartis Pharmaceuticals at Novartis AG since July 1, 2016 until 2019. Mr. Hud ...

Management Age and Tenure


Average Tenure


Average Age

Experienced Management: SAN's management team is seasoned and experienced (7.8 years average tenure).

Board Age and Tenure


Average Tenure


Average Age

Experienced Board: SAN's board of directors are considered experienced (7.8 years average tenure).

Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Management Team

  • Pierre Chancel (62yo)

    Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing

    • Tenure: 15.1yrs
  • Josep Catlla

    Head of Communications

    • Tenure: 0yrs
  • George Grofik

    Head of Investor Relations

    • Tenure: 0yrs
  • Karen Linehan (60yo)

    Executive VP of Legal Affairs & General Counsel

    • Tenure: 12.5yrs
  • Laurent Gilhodes

    Principal Accounting Officer and Vice President of Corporate Accounting

    • Tenure: 0yrs
  • Bruno Ménard

    Chief Information officer

    • Tenure: 8.1yrs
  • Dante Beccaria

    Global Compliance Officer & VP

    • Tenure: 7.4yrs
  • Jean-Baptiste de Chatillon (54yo)

    Executive VP & CFO

    • Tenure: 0.9yrs
  • Caroline Luscombe (59yo)

    Executive Vice President of Human Resources

    • Tenure: 0.9yrs
  • Paul Hudson (52yo)

    Chief Executive Officer

    • Tenure: 0yrs

Board Members

  • Carole Piwnica (61yo)

    Independent Director

    • Tenure: 8.8yrs
    • Compensation: €100.00k
  • Jean-François Dehecq (79yo)

    Honorary Chairman

    • Tenure: 9.3yrs
    • Compensation: €4.71m
  • Serge Weinberg (68yo)


    • Tenure: 9.3yrs
    • Compensation: €708.36k
  • Suet-Fern Lee (61yo)

    Independent Director

    • Tenure: 8.3yrs
    • Compensation: €117.50k
  • Patrick Kron (66yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: €132.50k
  • Fabienne Lecorvaisier (57yo)

    Independent Director

    • Tenure: 6.3yrs
    • Compensation: €127.50k
  • Claudie Haigneré (62yo)

    Independent Director

    • Tenure: 11.3yrs
    • Compensation: €107.50k
  • Diane Souza (67yo)

    Independent Director

    • Tenure: 3.3yrs
    • Compensation: €182.50k
  • Laurent Attal (61yo)


    • Tenure: 7.3yrs
    • Compensation: €107.50k
  • Thomas Südhof (64yo)

    Independent Director

    • Tenure: 3.3yrs
    • Compensation: €120.00k

Company Information

Sanofi's company bio, employee growth, exchange listings and data sources

Key Information

  • Name: Sanofi
  • Ticker: SAN
  • Exchange: SWX
  • Founded: 1973
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €99.119b
  • Listing Market Cap: €108.272b
  • Shares outstanding: 1.25b
  • Website: https://www.sanofi.com

Number of Employees


  • Sanofi
  • 54, Rue La Boétie
  • Paris
  • Ile-de-France
  • 75008
  • France


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SANSWX (SIX Swiss Exchange)YesOrdinary SharesCHCHFMay 1999
SANOWBAG (Wiener Boerse AG)YesOrdinary SharesATEURMay 1999
SANPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURMay 1999
SNWXTRA (XETRA Trading Platform)YesOrdinary SharesDEEURMay 1999
SANENXTPA (Euronext Paris)YesOrdinary SharesFREURMay 1999
SNWDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 1999
SNYN.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMay 1999
0O59LSE (London Stock Exchange)YesOrdinary SharesGBEURMay 1999
SANFBIT (Borsa Italiana)YesOrdinary SharesITEURMay 1999
SNY NBMV (Bolsa Mexicana de Valores)SPONSORED ADRMXMXNJul 2002
SNYNasdaqGS (Nasdaq Global Select)SPONSORED ADRUSUSDJul 2002


Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubag ...

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/11 20:45
End of Day Share Price2019/06/14 00:00
Annual Earnings2018/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.